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Abstract
Background: In regenerative therapy, self-clotted platelet concentrates, such as platelet-rich fibrin (PRF), are
generally prepared on-site and are immediately used for treatment. If blood samples or prepared clots can be
preserved for several days, their clinical applicability will expand. Here, we prepared PRF from stored whole-blood
samples and examined their characteristics.
Methods: Blood samples were collected from non-smoking, healthy male donors (aged 27–67 years, N = 6), and
PRF clots were prepared immediately or after storage for 1–2 days. Fibrin fiber was examined by scanning electron
microscopy. Bioactivity was evaluated by means of a bioassay system involving human periosteal cells, whereas
PDGF-BB concentrations were determined by an enzyme-linked immunosorbent assay.
Results: Addition of optimal amounts of a 10% CaCl2 solution restored the coagulative ability of whole-blood
samples that contained an anticoagulant (acid citrate dextrose) and were stored for up to 2 days at ambient
temperature. In PRF clots prepared from the stored whole-blood samples, the thickness and cross-links of fibrin
fibers were almost identical to those of freshly prepared PRF clots. PDGF-BB concentrations in the PRF extract were
significantly lower in stored whole-blood samples than in fresh samples; however, both extracts had similar
stimulatory effects on periosteal-cell proliferation.
Conclusions: Quality of PRF clots prepared from stored whole-blood samples is not reduced significantly and can
be ensured for use in regenerative therapy. Therefore, the proposed method enables a more flexible treatment
schedule and choice of a more suitable platelet concentrate immediately before treatment, not after blood
collection.
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Background
Blood preservation is generally and widely used in the
fields of blood transfusion and surgery for either autolo-
gous or allogeneic blood [1–3]. In case of small lots of
blood-derived materials used in regenerative therapy,
such as platelet concentrates, it is generally accepted
that autologous blood samples should be collected on-
site and immediately centrifuged for processing [4].
Accordingly, it is officially recommended to use thus
prepared materials immediately. The advantages of this
preparation protocol are the zero cost of preservation
and no risk of degradation and contamination.
In Niigata University Hospital, when relatively severe
surgical operations (e.g., large bone defects that require
hospitalization for alveolar ridge augmentation and sinus
floor elevation) are planned, relatively large volumes of
blood samples are usually collected the day before the
operation, and platelet-rich plasma (PRP) is prepared
and stored at ambient temperature until use [5]. Never-
theless, there are no established methods for preparation
of self-clotted platelet concentrates from stored whole-
blood (WB) samples. This may be another reason why
platelet-rich fibrin (PRF) should be prepared on-site and
used immediately.
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On the other hand, if PRF can be prepared from stored
WB samples on the next day or later without significant
reduction in the bioactivity, clinical applications of PRF
will expand. In this study, we developed a method for
preparation of PRF from stored WB samples by adding
CaCl2 and evaluated the quality in terms of suitability
for regenerative therapy. As a result, we successfully vali-
dated the method and ensured the quality of PRF pre-
pared from stored WB samples.
Methods
Blood collection, preservation, and PRF preparation
The study design and consent forms for all proce-
dures performed on the study subjects were ap-
proved by the ethics committee for human subjects
at Niigata University School of Medicine in accord-
ance with the Helsinki Declaration of 1975 as revised
in 2008.
With informed consent, blood samples (~9.0 mL per
tube) were collected from six non-smoking, healthy,
male volunteers (27 to 67 years old) using 21-gauge nee-
dles equipped with conventional vacuum plain glass tube
(Plain BD Vacutainer Tube; Becton, Dickinson and
Company, Franklin Lakes, NJ, USA) as described previ-
ously [6–8]. For preparation of control PRF by the con-
ventional method, the anticoagulant was not added.
Blood samples were immediately centrifuged or stored
by gentle mixing using a tube rotator at ambient
temperature (18–22 °C).
The blood samples collected with the anticoagulant
and stored for up to 2 days were centrifuged by means
of a Medifuge centrifugation system (Silfradent S.r.l.,
Santa Sofia, Italy). After elimination of the red blood cell
fractions, the resulting PRF clots, more specifically
termed as concentrated growth factors (CGF) [9], were
stored at −80 °C until measurement of growth factor
concentration.
Fig. 1 Glucose levels (a), calcium levels (b), and pH (c) of stored WB samples. Supernatant serum fractions were examined. Plasma fractions
prepared by quick centrifugation were used to determine calcium levels in fresh and stored WB samples that were not added CaCl2. N = 6
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For preparation of platelet-poor plasma (PPP), blood
samples (~9.0 mL) were collected from the same volun-
teers by means of plastic vacuum blood collection tubes
(Neotube®; NIPRO, Osaka, Japan) equipped with 21-
gauge needles, in the presence of 1.0 mL acid citrate
dextrose solution-A formulation (ACD-A; Terumo,
Tokyo, Japan), an anticoagulant [8, 10]. The blood sam-
ples were centrifuged on a KS-5000 centrifuge (Kubota,
Tokyo, Japan) equipped with a swing rotor at 1700 rpm
(530g) and 3000 rpm (1660g) for the first and second
spin (8 min), respectively. The resulting supernatant
fractions were collected as PPP preparations. To form fi-
brin clots, bovine thrombin (Liquid Thrombin
MOCHIDA softbottle, Mochida Pharmaceutical Co.,
Ltd., Tokyo, Japan) was added to PPP at a final volume
percentage of 2.5%.
Determination of glucose, calcium, and pH
WB samples were quickly centrifuged at 1500 rpm for
3 min to prepare plasma fraction, which were subjected
to determine total free calcium levels using a commer-
cial kit based on MXB method (Calcium E-test WAKO;
Wako Pure Chemicals, Osaka, Japan).
Stored WB samples were then mixed intermittently
with 200 μL (20 μL × 10 times) of 10% CaCl2 solution
and centrifuged by a Medifuge centrifugation system
to prepare PRF. When lower amounts of CaCl2 were
added, PRF clots were less reproducibly prepared.
When higher amounts of CaCl2 were added intermit-
tently, or when the optimal amount of CaCl2 were
added at once, PRF clots were never prepared
(Kawase, unpublished observations).
The supernatant serum fractions were subjected to de-
termine calcium and glucose levels as described above
and using a commercial kit based on GOD method
(Glucose CII-test WAKO; Wako Pure Chemicals). The
serum fractions were also used to determine pH levels
by pH indicators (MColorHast; EMD Millipore Corp.,
Billerica, MA, USA).
A bioassay on human periosteal cells
The frozen PRF samples were minced with scissors and
homogenized using a disposable homogenizer (Bio-
Masher II, Nippi, Tokyo, Japan). After high-speed centri-
fugation (7340g), supernatants (PRF extracts) were
collected and used for the bioassay described below and
for measurement of growth factor levels.
Because alveolar periosteum strongly contributes to
regeneration of periodontal skeletal tissue [11], we used
human alveolar bone-derived periosteal cells for evalu-
ation of the potency and efficacy of PRF preparations.
The periosteal cells were obtained and expanded as de-
scribed elsewhere [8, 12]. With informed consent,
human periosteum tissue segments were aseptically ex-
cised from the periodontal tissue on the healthy buccal
side of the retromolar region of the mandibles of two
non-smoking female volunteers (age = 19 and 29). Small
periosteum pieces were expanded to form multilayered
cellular periosteal sheets (∅ 30–40 mm), and then these
sheets were enzymatically digested with 0.05% trypsin
plus 0.52 mM EDTA (Invitrogen, Carlsbad, CA, USA) to
release single cells. After expansion in monolayer cul-
tures, the cells were seeded at a density of 0.4 × 104 per
well in 24-well plates and treated with PRF extracts (0,
0.5, 1, 2, or 4%) for 72 h in DMEM containing 1% of
fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Six
different lots of PRF extracts were used for each ex-
periment. At the end of the incubation periods, the
cells were harvested using 0.05% trypsin plus
0.53 mM EDTA and immediately counted on an au-
tomated cell counter (Moxi-z; ORLFO Technologies,
Ketchum, ID, USA) (N = 6) [13].
Fig. 2 Appearance of PRF clots prepared from WB samples stored
for 2 days. These observations are representative of WB samples
obtained from four donors
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Quantification of a growth factor by an enzyme-linked
immunosorbent assay (ELISA)
PRF extracts prepared as described above were subjected
to measurement of PDGF-BB levels using the Human
PDGF-BB Quantikine ELISA Kit (R&D Systems, Inc.,
Minneapolis, MN, USA) as described previously [8].
Scanning electron microscopy (SEM)
The PRF clots that were compressed in a stainless-steel
compressor were fixed with 2.5% neutralized glutaralde-
hyde, dehydrated with a series of ethanol solutions and
t-butanol, freeze-dried, and then examined under a scan-
ning electron microscope (TM-1000, Hitachi, Tokyo,
Japan) with an accelerating voltage of 15 kV, as described
elsewhere [7, 14].
Statistical analysis
The data were expressed as mean ± standard deviation
(SD). For multigroup comparisons, statistical analyses
were conducted to compare the mean values by one-way
analysis of variance (ANOVA) followed by Tukey’s
multiple-comparison test (SigmaPlot 12.5; Systat Soft-
ware, Inc., San Jose, CA, USA). Differences with P values
<0.05 were considered significant.
Results
Glucose and calcium contents and pH of WB or serum
samples after centrifugation are shown in Fig. 1. Because
glucose is contained in the ACD-A solution, glucose
levels in the stored WB and serum samples (see Fig. 4c)
after centrifugation were significantly greater than those
of freshly collected WB samples. Total free calcium
levels, including calcium chelated by citrate, in WB sam-
ples decreased significantly during storage and were sig-
nificantly increased by addition of a 10% CaCl2 solution.
The pH levels of freshly collected WB samples were
6.0–6.5, and similar pH was observed in stored WB sam-
ples. Addition of the ACD-A solution (~10%) did not
significantly decrease the pH of the stored WB samples.
For reference, pH of ACD-A solution was 4.5–5.0.
The appearance of PRF clots prepared from freshly
collected WB samples and WB samples stored for 2 days
are shown in Fig. 2. There were no visual differences be-
tween these two PRF preparations. Microstructure of fi-
brin clots formed from fresh and 2-day-old WB samples
is shown in Fig. 3. As for thickness and cross-links of fi-
brin fibers, no substantial differences were observed. For
reference, fibrin clots that were prepared from PPP and
bovine thrombin were composed of apparently thinner
fibrin fibers as compared with PRF clots from either
fresh or stored WB samples.
The biological activity was tested on human periosteal
cells. The effects of PRF extracts on the cell proliferation
are shown in Fig. 4a. PRF extracts (0–4%) prepared from
fresh, 1-day-old, and 2-day-old WB samples exerted
similar stimulatory effects on the proliferation of
Fig. 3 SEM examination of fibrin fibers formed in self-clotted PRF and thrombin-stimulated PPP clots. PRF was prepared from fresh and 2-day-old
WB samples. Similar observations were obtained from WB samples collected from three other donors. Scale bars = 10 μm
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periosteal cells. PDGF-BB concentrations in PRF extracts
prepared from fresh and stored WB samples are shown
in Fig. 4b. PRF extracts and the supernatant serum frac-
tion (see Fig. 4c) were subjected to measurement of
PDGF-BB levels. The concentration of this representa-
tive growth factor of platelet concentrates [4] was signifi-
cantly reduced in PRF extracts by storage. In contrast,
PDGF-BB levels noticeably (but not significantly) in-
creased in the supernatants.
Discussion
Platelet preservation is restricted to 3 and 5 days in Japan
and worldwide, respectively. This limit is based on the fact
that platelets are sensitive to changes in temperature and
pH: when samples are stored at 2 to 6 °C, platelets become
unsuitable for production of platelet concentrates [3].
Preservation of platelet concentrates results in a drop of
pH below 6.0 depending on the platelet count [15], and
pH below 6.2 correlates with decreased in vivo efficacy of
platelets [16]. Furthermore, it was recently demonstrated
that growth factors in PRP degrade in the course of stor-
age at 22 °C [17].
On the other hand, in general, WB can be stored in
the presence of ACD or citrate phosphate and dextrose
(CPD) at room temperature for a relatively long period
(3 weeks or longer) before it is processed into blood
components [1]. The WB storage has also been sup-
ported by recent developments in oxygen-permeable
plastic bags. Nevertheless, out of concern about bacterial
contamination, the maximal storage period is restricted
Fig. 4 Bioactivities and PDGF-BB concentrations in PRF extracts and the supernatant serum fraction. a PRF extracts were added to periosteal cell
cultures and incubated for 3 days to evaluate their effects on cell proliferation. No significant differences were observed among three groups. b
PRF extracts were subjected to measurement of PDGF-BB levels using an ELISA kit. No significant differences were observed in the supernatant
among three groups. N = 6. c Representative localization of supernatant serum fraction of PRF preparation just after centrifugation
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to 8 h in some countries [3]. To minimize and prevent
bacterial proliferation, it is recommended to maintain
white blood cells in WB samples during the initial 16 to
20 h of storage to digest bacteria during storage [18, 19].
Here, it is worth discussing which functional states of
platelets are expected to be maintained during storage
for subsequent preparation of platelet concentrates (to
be used for regenerative therapy). There is no doubt that
the functional states observed in freshly isolated platelets
are the best for preparation of platelet concentrates and
for their best clinical performance. Nevertheless, given
that platelet concentrates are expected to provide signifi-
cant amounts of growth factors and fibrin(ogen) at im-
plantation sites, stored platelets are not necessarily
expected to function as fully as fresh ones (e.g., in terms
of aggregation). Rather, stored platelets are expected not
to lose growth factors during the storage period, while
coagulation factors, especially those involved in the en-
dogenous coagulation cascade, should maintain their ac-
tivities to convert and polymerize fibrinogen to form
well cross-linked fibrin fibers.
Considering the current status of clinical use of platelet
concentrates in the fields of periodontology and oral sur-
gery, in this study, we used 10-mL glass tubes that are not
oxygen-permeable instead of oxygen-permeable plastic
bags for storage of large volumes of WB or platelets. We
advanced a working hypothesis that the storage of WB
samples in glass tubes would result in a more rapid and
substantial pH drop and inactivation of several enzymes
involved in coagulation. This study revealed that addition
of an optimal amount of a CaCl2 solution successfully re-
stored the coagulation ability of the anticoagulant-
supplemented WB samples. The fibrin fibers prepared
from the stored WB samples were almost identical to
those of fresh WB samples. PDGF-BB concentrations were
significantly lower in PRF extracts prepared from stored
WB samples than in those of fresh WB samples. This ef-
fect can be explained by a growth factor release from plate-
lets after stimulation by calcium ions or maybe (less likely)
by degradation of PDGF-BB. Nonetheless, the bioactivities
did not significantly worsen during the short storage.
In general, autologous platelet concentrates are prepared
and immediately used for regenerative therapy in dental
clinics at present. Our method should expand the clinical
applicability of platelet concentrates, especially PRF prepa-
rations, and make the treatment schedule more flexible.
Conclusions
The self-clotted types of platelet concentrates (PRF) can
be prepared from ACD-containing stored WB by
addition of CaCl2 without a significant reduction in their
bioactivity and without other specific reagents or de-
vices. This approach should contribute to dissemination
of PRF therapy.
Abbreviations
ACD: Acid citrate dextrose solution; CGF: Concentrated growth factors;
CPD: Citrate phosphate and dextrose; EDTA: Ethylenediaminetetraacetic acid;
PDGF: Platelet-derived growth factor; PPP: Platelet-poor plasma; PRF: Platelet-
rich fibrin; PRP: Platelet-rich plasma; SEM: Scanning electron microscope;
WB: Whole blood
Authors’ contributions
KI, MS, TW, YK, and TK conceived and designed the study, performed the
experiments, and wrote the manuscript. TS, HK, MN, TO, KU, and TT
performed the experiments and data analysis. HO and KN participated in the
manuscript preparation. All authors read and approved the final version of
the manuscript.
Competing interests
Kazushige Isobe, Masashi Suzuki, Taisuke Watanabe, Yutaka Kitamura, Taiji
Suzuki, Hideo Kawabata, Toshimitsu Okudera, Hajime Okudera, Kohya
Uematsu, Koh Nakata, Takaaki Tanaka, and Tomoyuki Kawase declare that
they have no competing interests.
Ethics approval and consent to participate
The study design and consent forms for all procedures performed on the
study subjects were approved by the ethics committee for human subjects
at Niigata University School of Medicine in accordance with the Helsinki
Declaration of 1975 as revised in 2008.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Tokyo Plastic Dental Society, Kita-ku, Tokyo, Japan. 2Division of Oral
Implantology, Niigata University Medical and Dental Hospital, Niigata, Japan.
3Bioscience Medical Research Center, Niigata University Medical and Dental
Hospital, Niigata, Japan. 4Department of Materials Science and Technology,
Niigata University, Niigata, Japan. 5Division of Oral Bioengineering, Institute of
Medicine and Dentistry, Niigata University, Niigata, Japan.
Received: 21 December 2016 Accepted: 15 February 2017
References
1. Hess J. Conventional blood banking and blood component storage
regulation: opportunities for improvement. Blood Transfus. 2010;8 Suppl 3:
s9–s15.
2. World Health Organization. Manual on the management, maintenance and
use of blood cold chain equipment. http://www.who.int/bloodsafety/
Manual_on_Management,Maintenance_and_Use_of_Blood_Cold_Chain_
Equipment.pdf. Accessed 26 Nov 2016.
3. van der Meer PF, de Wildt-Eggen J. The effect of whole-blood storage time
on the number of white cells and platelets in whole blood and in white
cell-reduced red cells. Transfusion. 2006;46:589–94.
4. Kawase T. Platelet-rich plasma and its derivatives as promising bioactive
materials for regenerative medicine: basic principles and concepts
underlying recent advances. Odontology. 2015;103:126–35.
5. Nagata M, Hoshina H, Li M, Arasawa M, Uematsu K, Ogawa S, Yamada K,
Kawase T, Suzuki K, Ogose A, Fuse I, Okuda K, Uoshima K, Nakata K, Yoshie
H, Takagi R. A clinical study of alveolar bone tissue engineering with
cultured autogenous periosteal cells: coordinated activation of bone
formation and resorption. Bone. 2012;50:1123–9.
6. Kobayashi M, Kawase T, Okuda K, Wolff LF, Yoshie H. In vitro immunological
and biological evaluations of the angiogenic potential of platelet-rich fibrin
preparations: a standardized comparison with PRP preparations. Int J
Implant Dent. 2015;1:31.
7. Kobayashi M, Kawase T, Horimizu M, Okuda K, Wolff LF, Yoshie H. A
proposed protocol for the standardized preparation of PRF membranes for
clinical use. Biologicals. 2012;40:323–9.
8. Masuki H, Okudera T, Watanebe T, Suzuki M, Nishiyama K, Okudera H,
Nakata K, Uematsu K, Su CY, Kawase T. Growth factor and pro-inflammatory
cytokine contents in platelet-rich plasma (PRP), plasma rich in growth
Isobe et al. International Journal of Implant Dentistry  (2017) 3:6 Page 6 of 7
factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated
growth factors (CGF). Int J Implant Dent. 2016;2:19.
9. Corigliano M, Sacco L, Baldoni E. CGF-una proposta terapeutica per la
medicina rigenerativa. Odontoiatria. 2010;1:69–81.
10. Kawase T, Okuda K, Wolff LF, Yoshie H. Platelet-rich plasma-derived fibrin
clot formation stimulates collagen synthesis in periodontal ligament and
osteoblastic cells in vitro. J Periodontol. 2003;74:858–64.
11. Duan X, Bradbury SR, Olsen BR, Berendsen AD. Matrix Biol. 2016;52-54:127–40.
12. Kawase T, Okuda K, Kogami H, Nakayama H, Nagata M, Nakata K, Yoshie H.
Characterization of human cultured periosteal sheets expressing bone-
forming potential: in vitro and in vivo animal studies. J Tissue Eng Regen
Med. 2009;3:218–29.
13. Kawase T, Hayama K, Tsuchimochi M, Nagata M, Okuda K, Yoshie H, Burns
DM, Nakata K. Evaluating the safety of somatic periosteal cells by flow-
cytometric analysis monitoring the history of DNA damage. Biopreserv
Biobank. 2016;14:129–37.
14. Horimizu M, Kawase T, Nakajima Y, Okuda K, Nagata M, Wolff LF, Yoshie H.
An improved freeze-dried PRP-coated biodegradable material suitable for
connective tissue regenerative therapy. Cryobiology. 2013;66:223–32.
15. de Wildt-Eggen J, Schrijver JG, Bouter-Valk HJ, Fijnheer R, Bins M, van
Prooijen HC. Improvement of platelet storage conditions by using new
polyolefin containers. Transfusion. 1997;37:476–81.
16. Murphy S, Rebulla P, Bertolini F, Holme S, Moroff G, Snyder E, Stromberg R.
In vitro assessment of the quality of stored platelet concentrates. The BEST
(Biomedical Excellence for Safer Transfusion) Task Force of the International
Society of Blood Transfusion. Transfus Med Rev. 1994;8:29–36.
17. Sonker A, Dubey A. Determining the effect of preparation and storage: an
effort to streamline platelet components as a source of growth factors for
clinical application. Transfus Med Hemother. 2015;42:174–80.
18. Hogman CF, Gong J, Hambraeus A, Johansson CS, Eriksson L. The role of
white cells in the transmission of Yersinia enterocolitica in blood
components. Transfusion. 1992;32:654–7.
19. Pietersz RN, Reesink HW, Pauw W, Dekker WJ, Buisman L. Prevention of
Yersinia enterocolitica growth in red-blood-cell concentrates. Lancet. 1992;
340:755–6.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Isobe et al. International Journal of Implant Dentistry  (2017) 3:6 Page 7 of 7
